Analyst Notes: KOLs excited by the PCSK9 inhibitors, but long term safety and cost concerns remain (now in podcast format)

FirstWord's Basharut Syed - senior analyst - and Dr Duncan Emerton - Senior Director, Syndicated Insights & Analysis - discuss some of the key findings from the forthcoming KOL Insight: dyslipidemia report

To read more Analyst Notes articles, click here.

Reference Articles